BR112014009330A2 - solução para administração oral - Google Patents

solução para administração oral

Info

Publication number
BR112014009330A2
BR112014009330A2 BR112014009330A BR112014009330A BR112014009330A2 BR 112014009330 A2 BR112014009330 A2 BR 112014009330A2 BR 112014009330 A BR112014009330 A BR 112014009330A BR 112014009330 A BR112014009330 A BR 112014009330A BR 112014009330 A2 BR112014009330 A2 BR 112014009330A2
Authority
BR
Brazil
Prior art keywords
acid
oral administration
solution
salt
compound
Prior art date
Application number
BR112014009330A
Other languages
English (en)
Inventor
Okamoto Ayako
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112014009330A2 publication Critical patent/BR112014009330A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/191Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1 / 1 resumo “soluã‡ãƒo para administraã‡ãƒo oral” ㉠fornecida uma soluã§ã£o adequada para a administraã§ã£o oral de 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona (composto (i)) ou um sal do mesmo. uma soluã§ã£o para administraã§ã£o oral contendo o composto (i) ou um sal do mesmo, e pelo menos um composto selecionado do grupo que consiste de ã¡cido lã¡tico, ã¡cido fosfã³rico, ã¡cido glicã³lico, ã¡cido mã¡lico, ã¡cido tartã¡rico, ã¡cido cã­trico, ã¡cido succã­nico e ã¡cido acã©tico e tendo o ph de 2,5 a 4,5.
BR112014009330A 2011-10-19 2012-10-19 solução para administração oral BR112014009330A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161548859P 2011-10-19 2011-10-19
PCT/JP2012/077668 WO2013058411A1 (en) 2011-10-19 2012-10-19 Solution for oral administration

Publications (1)

Publication Number Publication Date
BR112014009330A2 true BR112014009330A2 (pt) 2017-04-11

Family

ID=47178263

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009330A BR112014009330A2 (pt) 2011-10-19 2012-10-19 solução para administração oral

Country Status (35)

Country Link
US (7) US20140303183A1 (pt)
EP (1) EP2768508B1 (pt)
JP (1) JP6077534B2 (pt)
KR (1) KR101856283B1 (pt)
CN (2) CN103889426A (pt)
AR (1) AR088372A1 (pt)
AU (2) AU2012326978B2 (pt)
BR (1) BR112014009330A2 (pt)
CA (1) CA2851999C (pt)
CL (1) CL2014000967A1 (pt)
CO (1) CO6950486A2 (pt)
CY (1) CY1117794T1 (pt)
DK (1) DK2768508T3 (pt)
EA (2) EA202190445A2 (pt)
ES (1) ES2583137T3 (pt)
HK (1) HK1196773A1 (pt)
HR (1) HRP20160989T1 (pt)
HU (1) HUE028869T2 (pt)
IL (1) IL231988A (pt)
IN (1) IN2014DN02987A (pt)
JO (1) JO3190B1 (pt)
LT (1) LT2768508T (pt)
ME (1) ME02459B (pt)
MX (1) MX347309B (pt)
MY (1) MY169096A (pt)
PL (1) PL2768508T3 (pt)
PT (1) PT2768508T (pt)
RS (1) RS54967B1 (pt)
SG (1) SG11201401273SA (pt)
SI (1) SI2768508T1 (pt)
SM (1) SMT201600341B (pt)
TW (2) TWI632921B (pt)
UA (1) UA111506C2 (pt)
WO (1) WO2013058411A1 (pt)
ZA (1) ZA201402669B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
RU2627423C1 (ru) * 2016-06-29 2017-08-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
RU2633635C1 (ru) * 2016-06-29 2017-10-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
UA124498C2 (uk) * 2015-12-01 2021-09-29 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Фармацевтична композиція для лікування інфекційно-запальних захворювань місцевого застосування і спосіб її одержання та застосування (варіанти)
WO2017095265A1 (ru) * 2015-12-01 2017-06-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
JP6786240B2 (ja) * 2016-03-31 2020-11-18 小林製薬株式会社 粘性経口組成物
EP3582765B1 (en) * 2017-10-10 2021-04-28 Vertice Pharma, LLC Midodrine hydrochloride oral solution and uses thereof
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
US20210401879A1 (en) * 2020-06-30 2021-12-30 Vireo Systems, Inc. Compositions for controlling odor and itch and methods of and devices for administering same
WO2022218356A1 (zh) * 2021-04-13 2022-10-20 上海博志研新药物技术有限公司 一种布瑞哌唑口溶膜组合物、其制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420077A (en) * 1972-04-14 1976-01-07 Unilever Ltd Process for imparting or enhancing fresh cheese flavour in a food digital transmission systems
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
WO2003092580A2 (en) * 2002-05-03 2003-11-13 Israel Institute For Biological Research Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
WO2005102369A1 (ja) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. 細菌細胞壁骨格成分を含有する製剤
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
CN101198331B (zh) * 2005-06-13 2012-05-02 大日本住友制药株式会社 增溶化制剂
ES2368758T3 (es) * 2005-09-01 2011-11-22 Baxter International Inc. (A Delaware Corporation) Formulación de argatroban que incluye un ácido como solubilizante.
US20100004267A1 (en) * 2006-07-31 2010-01-07 Asubio Pharma Co., Ltd. Liquid preparation
AU2008301925A1 (en) * 2007-09-17 2009-03-26 Merck Sharp & Dohme Corp. Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
AU2008302201A1 (en) * 2007-09-21 2009-03-26 Astrazeneca Ab Soluble dosage forms containing cephem derivatives suitable for parenteral administration
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
WO2012026562A1 (en) * 2010-08-24 2012-03-01 Otsuka Pharmaceutical Co., Ltd. Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
CN102119922A (zh) * 2011-03-03 2011-07-13 天津市炜杰科技有限公司 以酸作为增溶剂的21(s)阿加曲班静脉注射液
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組,以及彼之用途

Also Published As

Publication number Publication date
ME02459B (me) 2017-02-20
PL2768508T3 (pl) 2016-12-30
SG11201401273SA (en) 2014-05-29
PT2768508T (pt) 2016-08-17
JP2014530801A (ja) 2014-11-20
MX347309B (es) 2017-04-21
US20160213665A1 (en) 2016-07-28
TWI679977B (zh) 2019-12-21
IL231988A (en) 2017-09-28
US20200171023A1 (en) 2020-06-04
KR20140083032A (ko) 2014-07-03
JO3190B1 (ar) 2018-03-08
CA2851999C (en) 2020-01-07
HRP20160989T1 (hr) 2016-10-07
HUE028869T2 (en) 2017-01-30
SMT201600341B (it) 2016-11-10
US20210236483A1 (en) 2021-08-05
AU2012326978B2 (en) 2017-08-31
US20140303183A1 (en) 2014-10-09
UA111506C2 (uk) 2016-05-10
LT2768508T (lt) 2016-09-12
US20240009186A1 (en) 2024-01-11
TWI632921B (zh) 2018-08-21
AR088372A1 (es) 2014-05-28
HK1196773A1 (zh) 2014-12-24
CN107823131A (zh) 2018-03-23
CY1117794T1 (el) 2017-05-17
US20170182036A1 (en) 2017-06-29
IN2014DN02987A (pt) 2015-05-08
EA201490812A1 (ru) 2014-09-30
ES2583137T3 (es) 2016-09-19
CA2851999A1 (en) 2013-04-25
IL231988A0 (en) 2014-05-28
AU2012326978A1 (en) 2014-05-22
TW201737916A (zh) 2017-11-01
TW201330873A (zh) 2013-08-01
MY169096A (en) 2019-02-18
CN103889426A (zh) 2014-06-25
US20180271858A1 (en) 2018-09-27
KR101856283B1 (ko) 2018-05-09
RS54967B1 (sr) 2016-11-30
DK2768508T3 (en) 2016-08-29
MX2014004529A (es) 2014-08-01
ZA201402669B (en) 2015-09-30
AU2017213570A1 (en) 2017-08-31
SI2768508T1 (sl) 2016-09-30
JP6077534B2 (ja) 2017-02-08
NZ623523A (en) 2015-12-24
CL2014000967A1 (es) 2014-10-03
EP2768508B1 (en) 2016-07-06
EA202190445A2 (ru) 2021-08-31
WO2013058411A1 (en) 2013-04-25
CO6950486A2 (es) 2014-05-20
EP2768508A1 (en) 2014-08-27

Similar Documents

Publication Publication Date Title
BR112014009330A2 (pt) solução para administração oral
EA201592055A1 (ru) 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
MX2013004298A (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa.
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
UA107951C2 (en) Imidazopyridine derivatives as inhibitors of jak
WO2010108074A3 (en) Inhibitors of pi3 kinase
CA2757418C (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
MX2011010415A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
IN2014CN01024A (pt)
MX2012003007A (es) Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
BR112013022213A2 (pt) administração parenteral de tapentadol
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
UA103500C2 (uk) Сульфоксимінзаміщені анілінопіримідинові похідні як cdk-інгібітори, їх одержання й застосування як лікарських засобів
NZ596628A (en) Ketolide compounds having antimicrobial activity
WO2018201167A3 (en) Propionic acid derivatives and methods of use thereof
MX2014001495A (es) Formulaciones de acido desoxicolico y sales del mismo.
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
BR112015026840A2 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto, e, método prevenir ou tratar hiperfosfatemia
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
PH12014501425A1 (en) Pharmaceutical preparation comprising brexpiprazole and substituted beta-cyclodextrin
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
WO2012017448A3 (en) Salts of lapatinib
BR112012013918A2 (pt) inibidores de diacil glicerol acil transferase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]